View All Key Stats
EXEL Key Stats
| Income Statement | |
| Revenue (TTM) | 256.91M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 0.01 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 3.524M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 96.04% |
| Profit Margin (Quarterly) | 20.65% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0 |
| Price and Valuation | |
| Market Cap | 8.155B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 29.39 |
| PE Ratio (TTM) | 2788.00 |
| Price to Book Value | 68.10 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 0.9465 |
| Free Cash Flow (Quarterly) | 68.05M |
| Return on Equity (TTM) | -17.45% |
View All EXEL News
EXEL News
-
WireHeadlineTime (ET)
-
Yahoo07/25 16:25
-
Yahoo07/24 10:44
-
PR Newswire07/24 06:40
-
Yahoo07/21 14:42
-
Yahoo07/21 12:57
-
Yahoo07/20 18:19
-
SA Breaking News07/20 10:33
-
MT Newswires07/20 07:21
-
Business Wire07/20 07:00
-
Yahoo07/19 10:16
View All Events
EXEL Events
| Date | Type | Description |
|---|---|---|
| 08/02/2017 17:00 EDT | Misc | Exelixis Inc Second Quarter Earnings Conference Call in 2017 |
| 08/02/2017 | Earnings | Exelixis Inc Second Quarter Earnings in 2017 Release |
| 07/20/2017 | Misc | Exelixis Announces Settlement of Dispute With Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib |
| 05/24/2017 | Misc | Exelixis Inc Annual General Meeting in 2016 |
| 05/01/2017 17:00 EDT | Misc | Exelixis Inc First Quarter Earnings Conference Call in 2017 |
| 05/01/2017 | Earnings | Exelixis Inc First Quarter Earnings in 2017 Release |
| 03/01/2017 | Misc | Exelixis Announces Webcasts of Investor Conference Presentations in March |
| 02/27/2017 17:00 EST | Misc | Exelixis Inc Fourth Quarter Earnings Conference Call in 2016 |
| 02/27/2017 | Earnings | Exelixis Inc Fourth Quarter Earnings in 2016 Release |
| 11/03/2016 17:00 EDT | Misc | Exelixis Inc Third Quarter Earnings Conference Call in 2016 |
EXEL Fundamentals
Income Statement View Statement
EXEL Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
EXEL One Page Reports
- One Page Report Download
EXEL Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Target Price | |
| Price | 27.88 |
| Price Target | Upgrade |
Edit
Profile
- URL: http://www.exelixis.com
- Investor Relations URL: http://www.exelixis.com/investors-media
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Next Earnings Release: Aug. 02, 2017
- Last Earnings Release: May. 01, 2017
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Exelixis Inc is a part of the healthcare sector. As a biotechnology company, it develops small molecule therapies for the treatment of cancer.
EXEL Comparables
EditEXEL Excel Add-In Codes
- Name: =YCI("EXEL","name")
- Description: =YCI("EXEL","description")
- Sector: =YCI("EXEL","sector")
- Industry: =YCI("EXEL","industry")
- Est. Current Fiscal Year End: =YCI("EXEL","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other EXEL Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXEL Tweets Stocktwits
Advertisement
